A Agilent Technologies Inc.

Agilent Expands Cross-Vendor CDS Instrument Control

(NYSE: A) today announced the latest implementation of its mutual compatibility philosophy. Now, joint customers of Agilent Technologies and Thermo Fisher Scientific can choose a chromatography data system from either company— or —to control analytical instruments from both organizations.

The two companies recognize that reliable multivendor instrument control is critical to the successful operation of today’s analytical laboratories. Using a single data system increases lab productivity by saving substantial time managing software, training staff, and making it easier to meet the regulations that govern the lab.

“Agilent's multivendor control approach to laboratory informatics allows our customers to select the best hardware and software for their needs,” said John Sadler, vice president and general manager of Agilent's Software and Informatics Division. “That is why we invest in integrating third-party analytical instruments into our OpenLab software suite, in collaboration with other analytical instrument manufacturers. Our goal is to provide simple and complete support for our mutual customers.”

Agilent OpenLab CDS streamlines laboratory operations with a single, secure data system that combines chromatography and mass spectrometry into one software platform. OpenLab CDS is a multivendor platform controlling Agilent GC, LC, single quadrupole GC/MS, LC/MS instruments along with many other instrument vendors.

Thermo Fisher Scientific instrument families are the latest additions to OpenLab CDS multivendor control program. OpenLab CDS tools provide time-saving steps in the analysis, interpretation, and reporting workflows, enabling users to quickly identify key information, improve turnaround time, and ensure the highest level of data integrity.

“The lack of interoperability between different vendors’ instruments and software has traditionally presented a barrier to laboratories adopting the right solutions to meet the unique needs of their workflows,” said Matt Hazlewood, senior director, global enterprise chromatography data systems, at Thermo Fisher Scientific. “The renewal of our commitment with Agilent for mutual compatibility and third-party control of instruments ensures that customers will have continued access to our market-leading Chromeleon CDS software platform, meaning they can deploy the analytical solutions they need without compromising the flexibility or efficiency of their workflows.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent . Follow Agilent on , , and .

EN
02/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch